Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Anemia » Anemia, Hemolytic » Anemia, Hemolytic, Congenital
Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Genetic Diseases, Inborn » Anemia, Hemolytic, Congenital
Description
Hemolytic anemia due to various intrinsic defects of the erythrocyte. MeSH
Hierarchy View
Subtype Terms (8)
Anemia, Dyserythropoietic, Congenital
1 approved drug
Anemia, Hemolytic, Congenital Nonspherocytic
Anemia, Sickle Cell
269 drugs (164 approved, 105 experimental)
Glucosephosphate Dehydrogenase Deficiency
12 drugs (5 approved, 7 experimental)
Spherocytosis, Hereditary
1 approved drug
Thalassemia
62 drugs (46 approved, 16 experimental)
Approved Indicated Drugs (1)
Phase 2 Indicated Drugs (3)
Organization Involved with Phase 3 Indications (2)
Organization Involved with Phase 2 Indications (3)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.